معرفی
Stephen Bergmeier is a Professor in the Department of Chemistry & Biochemistry at Ohio University's College of Arts and Sciences. He holds a Ph.D. in Medicinal Chemistry from the University of Michigan (1990). His research focuses on drug design, synthesis, and pharmaceutical engineering, with an emphasis on enzyme inhibition mechanisms (e.g., GSK-3β), computational modeling, and anti-inflammatory/anticancer therapeutics. Bergmeier has authored over 40 peer-reviewed articles and 10 patents, collaborating extensively with interdisciplinary teams on projects like SARS-CoV-2 spike protein inhibition and glucose transporter targeting in cancer.
Research highlights include the development of novel GSK-3 inhibitors for treating obesity-induced liver disease and severe COVID-19, as well as small-molecule inhibitors targeting cancer metabolism. His work bridges organic synthesis, computational biology, and medicinal chemistry to advance drug discovery. Bergmeier also contributes to Ohio University’s graduate programs, mentoring students in synthetic and medicinal chemistry.
His recent studies (2019-2024) explore structure-activity relationships, Markov state modeling for inhibitor dynamics, and preclinical evaluations in mouse models. While no formal awards are listed, his prolific publication record reflects sustained contributions to pharmacological research.
